EGFR and non-small cell lung carcinoma: In a series of clinical trials, third generation EGFR TKI osimertinib demonstrated a favorable toxicity profile and 70% objective response rate in EGFR-mutation positive NSCLC patients whose disease progressed on early generation EGFR TKIs (Goss et al., 2016; Mok et al., 2017).